Cerus (CERS) Other financing activities (2013 - 2023)

Cerus' (CERS) quarterly Other financing activities came in at -$168000.0 in Q4 2023, down 347.06% quarter-over-quarter from $68000.0 in Q3 2023.

Cerus (CERS) Other financing activities (2013 - 2023) Analysis & Trends

Cerus has disclosed Other financing activities across 3 years of filings, most recently posting -$168000.0 for Q4 2023.

Other financing activities for Q4 2023 came in at -$168000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $1.2 million (changed N/A YoY), and the FY2021 annual result was $1.0 million, changed N/A from the prior year.
Other financing activities came in at -$168000.0 for Q4 2023 at Cerus, down from $68000.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $68000.0 in Q3 2023 to a low of -$168000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	152.92 Bn	146.27 Bn	6.27 Bn
2	Stryker	119.50 Bn	116.62 Bn	3.81 Bn
3	Medtronic	102.71 Bn	94.54 Bn	5.76 Bn
4	Boston Scientific	69.72 Bn	68.51 Bn	3.61 Bn
5	Edwards Lifesciences	49.24 Bn	45.57 Bn	1.29 Bn
6	GE HealthCare Technologies	29.74 Bn	27.67 Bn	1.98 Bn
7	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
8	Dexcom	28.96 Bn	27.84 Bn	750.30 Mn
9	Steris	20.31 Bn	19.88 Bn	697.10 Mn
10	Cerus	496.03 Mn	416.34 Mn	27.89 Mn

Download Data